Skip to main content

Altimmune, Inc.

ALT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001326190

In the last 90 days, Altimmune, Inc. insiders filed 1 open-market purchase and 0 sales; 210 institutions reported holding it in 13F filings for Q2 2026, worth $460.7M in total; Viking Global Investors is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Altimmune, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
1 filing
1 insider, $44.3K in total
Open-market sells
0 filings
Insiders trading
1
Net value
+$44.3K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Altimmune, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Altimmune, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Richardson Linda MChief Commercial Officer17,174Sep 17, 20261
Durso Jerome BenedictPresident and CEO62,500Aug 13, 20266
Weaver Gregory LChief Financial Officer39,831Aug 3, 20266
Roberts M ScotChief Scientific Officer113,699Aug 3, 20265
Sayare MitchelDirector–May 1, 20262
Gill JohnDirector21,700May 1, 20264
Jorkasky DianeDirector527May 1, 20263
Sohn Catherine A.Director1,500May 1, 20263
Hodges PhilipDirector–May 1, 20262
Schafer KlausDirector9,179May 1, 20262
Pisano WayneDirector13,498May 1, 20263
Lawver Teri LDirector–May 1, 20262
Garg Vipin KDirector424,519Feb 2, 20263
Jordt Raymond MChief Business Officer70,107Feb 2, 20264
Arbet-Engels ChristopheChief Medical Officer–Oct 3, 20251
Harris Matthew ScottChief Medical Officer16,087Aug 4, 20250
Drutz DavidDirector55,524IndirectAug 20, 20240
Shutterly AndrewActing Chief Financial Officer11,372Aug 1, 20240
Eisenstadt Richard IChief Financial Officer45,012Feb 1, 20240
Brown William MichaelChief Financial Officer17,721Aug 6, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 13, 2026 (view filing)4:05 PM ETAug 13Same dayDurso Jerome BenedictPresident and CEOPPurchaseCommon Stock, par value $0.0001+15.0K$2.95+$44.3K+31.6%62.5K after
Apr 6, 2026 (view filing)Apr 6Same dayGill JohnDirectorPPurchaseCommon Stock, par value $0.0001+9.20K$3.41+$31.4K+73.6%21.7K after
Apr 1, 2026 (view filing)Apr 1Same dayDurso Jerome BenedictPresident and CEOPPurchaseCommon Stock, par value $0.0001+15.0K$3.14+$47.1K+46.2%47.5K after
Apr 1, 2026 (view filing)Apr 1Same dayWeaver Gregory LChief Financial OfficerPPurchaseCommon Stock, par value $0.0001+10.0K$3.15+$31.5K+35.6%38.1K after
Mar 9, 2026 (view filing)Mar 63 daysDurso Jerome BenedictPresident and CEOPPurchaseCommon Stock, par value $0.0001+20.0K$3.54+$70.8K+160.0%32.5K after
Mar 9, 2026 (view filing)Mar 63 daysWeaver Gregory LChief Financial OfficerPPurchaseCommon Stock, par value $0.0001+5.00K$3.54+$17.7K+21.7%28.1K after
Jan 9, 2026 (view filing)Jan 81 dayPisano WayneDirectorPPurchaseCommon Stock, par value $0.0001+5.00K$4.08+$20.4K+58.8%13.5K after
Jan 5, 2026 (view filing)Jan 5Same daySohn Catherine A.DirectorPPurchaseCommon Stock, par value $0.0001+500$4.24+$2.12K+50.0%1.50K after
Dec 29, 2025 (view filing)Dec 29Same dayJorkasky DianeDirectorPPurchaseCommon Stock, par value $0.0001+527$3.80+$2.00KNew position527 after
Dec 23, 2025 (view filing)Dec 23Same dayGill JohnDirectorPPurchaseCommon Stock, par value $0.0001+12.5K$4.10+$51.3KNew position12.5K after
Dec 22, 2025 (view filing)Dec 22Same dayDurso Jerome BenedictDirectorPPurchaseCommon Stock, par value $0.0001+12.5K$4.13+$51.6KNew position12.5K after
Mar 18, 2025 (view filing)Mar 171 daySohn Catherine A.DirectorPPurchaseCommon Stock, par value $0.0001+1.00K$5.78+$5.78KNew position1.00K after
Mar 14, 2025 (view filing)Mar 131 dayWeaver Gregory LChief Financial OfficerPPurchaseCommon Stock, par value $0.0001+10.0K$5.20+$52.0KNew position10.0K after
Aug 20, 2024 (view filing)Aug 191 dayDrutz DavidDirectorSSaleCommon Stock, par value $0.0001−16.0K$6.90−$110.5K−22.4%55.5K after2 lots
Aug 15, 2023 (view filing)Aug 15Same dayDrutz DavidDirectorPPurchaseCommon Stock, par value $0.0001+300$2.88+$864+1.0%29.8K after
Jul 6, 2023 (view filing)Aug 12, 2022328 daysLateGill JohnDirectorSSaleCommon Stock, par value $0.0001−2.71K$15.00−$40.7K−49.5%2.77K after
Mar 27, 2023 (view filing)Mar 234 daysDrutz DavidDirectorPPurchaseCommon Stock, par value $0.0001+9.00K$4.27+$38.4K+43.9%29.5K after
Mar 24, 2023 (view filing)Mar 24Same dayEisenstadt Richard IChief Financial OfficerPPurchaseCommon Stock, par value $0.0001+10.0K$4.31+$43.1K+83.3%22.0K after
Mar 23, 2023 (view filing)Mar 23Same dayHarris Matthew ScottChief Medical OfficerPPurchaseCommon Stock, par value $0.0001+10.0K$4.22+$42.2K+42.9%33.3K after
Dec 22, 2022 (view filing)Dec 22Same dayPisano WayneDirectorSSaleCommon Stock, par value $0.0001−20.0K$15.01−$300.2K−70.2%8.50K after
Sep 1, 2022 (view filing)Aug 311 dayGarg Vipin KPresident and CEOSSaleCommon Stock, par value $0.0001−20.0K$20.02−$400.4K−7.8%236.8K after
Aug 12, 2022 (view filing)Aug 12Same dayGarg Vipin KPresident and CEOSSaleCommon Stock, par value $0.0001−15.0K$15.06−$225.9K−5.5%259.8K after
Jul 5, 2022 (view filing)Jul 1-54 daysRoberts M ScotChief Scientific OfficerSSaleCommon Stock, par value $0.0001−37.2K$12.00−$446.0K−81.7%8.30K after2 lots
Jun 30, 2022 (view filing)Jun 291 dayRoberts M ScotChief Scientific OfficerSSaleCommon Stock, par value $0.0001−5.46K$12.00−$65.5K−23.6%17.7K after
Jun 28, 2022 (view filing)Jun 271 dayRoberts M ScotChief Scientific OfficerSSaleCommon Stock, par value $0.0001−37.4K$12.00−$448.2K−67.8%17.7K after
Jun 28, 2022 (view filing)Jun 271 dayJorkasky DianeDirectorSSaleCommon Stock, par value $0.0001−17.6K$11.75−$206.9K−100.0%0 after
Jun 16, 2022 (view filing)Jun 151 dayDrutz DavidDirectorPPurchaseCommon Stock, par value $0.0001+1.00K$8.00+$8.00K+5.3%20.0K after
May 25, 2022 (view filing)May 241 dayDrutz DavidDirectorPPurchaseCommon Stock, par value $0.0001+1.20K$4.50+$5.40K+6.7%19.0K after
Mar 2, 2022 (view filing)Feb 282 daysHarris Matthew ScottChief Medical OfficerSSaleCommon Stock, par value $0.0001−30.0K$7.52−$225.6K−72.2%11.5K after